Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01330472 | An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites | PHASE1 | COMPLETED | 16 | — | — | May 1, 2011 | Jun 1, 2011 | Jan 28, 2021 | 1 | Singapore |
| Arm | Type | Description |
|---|---|---|
| Xanax XR tablets 3 mg (sourced from Caugus) | ACTIVE_COMPARATOR | Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE) |
| Xanax XR tablets 3 mg (sourced from Barceloneta), | EXPERIMENTAL | Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST) |
| Name | Type | Description |
|---|---|---|
| Xanax XR tablets 3 mg (sourced from Caugus) | DRUG | Tablets, 3 mg, single dose |
| Xanax XR tablets 3 mg (sourced from Barceloneta) | DRUG | Tablets, 3 mg, single dose |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 20 and 55 years, inclusive. * An informed consent document signed and dated by the subject. Exclusion Criteria: * Evidence or history of clinically significant abnormality. * A positive urine drug screen. * Subjects who...